Patients with Renal cell carcinoma randomized to Everolimus +/- BNC105P (N=107)

15 Excluded
6 had no available H&E slide
8 had inadequate RNA concentration or negative A260/280 ratios
1 had low binding density

Patients with H&E for demarcation of tissue and adequate RNA concentration (N=92)

10 Excluded
10 had no PFS outcome data

Patient with available PFS and clinical benefit data (n=82)

Computational Workflow and analysis

Supplementary Figure S1. CONSORT diagram for the phase I/II trial of everolimus with and without BNC105P